Search

Search Constraints

You searched for: Date 2017 Author/Creator Bridges, Thomas M.

Search Results

1. Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. Issue 2 (15th January 2017)

2. Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides. Issue 23 (1st December 2017)

3. Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides. Issue 13 (1st July 2017)

4. Continued optimization of the M5 NAM ML375: Discovery of VU6008667, an M5 NAM with high CNS penetration and a desired short half-life in rat for addiction studies. Issue 6 (15th March 2017)

5. Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists. Issue 15 (1st August 2017)

6. Discovery of a novel 2, 4-dimethylquinoline-6-carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping. Issue 22 (15th November 2017)

7. Discovery of a novel, CNS penetrant M4 PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core. Issue 18 (15th September 2017)

8. Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. Issue 11 (1st June 2017)

9. Synthesis and evaluation of 4, 6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype. Issue 11 (1st June 2017)